REVIEW

Is there a role for HSF1 in viral infections?
Antonia Reyes¹, Areli J. Navarro¹, Benjamín Diethelm-Varela¹, Alexis M. Kalergis¹,² and Pablo A. González¹

¹ Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
² Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Keywords
heat shock; heat shock factor 1; HSF1; stress; viral infections

Correspondence
P. A. González, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Millennium Institute on Immunology and Immunotherapy, Pontificia Universidad Católica de Chile, Santiago-Chile. Av. Portugal 49, Santiago E-8330025, Chile
E-mail: pagonzalez@bio.puc.cl

Antonia Reyes and Areli J. Navarro contributed equally to this article

(Received 15 November 2021, revised 29 March 2022, accepted 27 April 2022)
doi:10.1002/2211-5463.13419

Cells undergo numerous processes to adapt to new challenging conditions and stressors. Heat stress is regulated by a family of heat shock factors (HSFs) that initiate a heat shock response by upregulating the expression of heat shock proteins (HSPs) intended to counteract cellular damage elicited by increased environmental temperature. Heat shock factor 1 (HSF1) is known as the master regulator of the heat shock response and upon its activation induces the transcription of genes that encode for molecular chaperones, such as HSP40, HSP70, and HSP90. Importantly, an accumulating body of studies relates HSF1 with viral infections; the induction of fever during viral infection may activate HSF1 and trigger a consequent heat shock response. Here, we review the role of HSF1 in different viral infections and its impact on the health outcome for the host. Studying the relationship between HSF1 and viruses could open new potential therapeutic strategies given the availability of drugs that regulate the activation of this transcription factor.

Heat shock factors (HSFs) are a family of transcription factors that are mostly activated in response to cell stress induced by heat, with heat shock factor 1 (HSF1) being the most studied component of this family [1–3]. HSF1 and other HSFs can bind to specific regions in the genome named heat shock response elements (HSE), which have known consensus sequences [4,5]. HSF1 is conserved from fungi to vertebrates and regulates the transcription of multiple genes, most of them oriented at easing cell damage elicited by heat stress [3,6]. HSFs can induce the transcription of a set of genes that encode proteins involved in the heat shock response (HSR), such as chaperones and heat shock proteins (HSPs), which play numerous roles in controlling cell deregulation produced by elevated environmental temperatures. More recently, the

Abbreviations
AIDS, acquired immunodeficiency syndrome; AKT, Akt serine/threonine kinase; ARE, AU-rich element; Atg7, autophagy-related protein 7; CaMKII, Ca²⁺/calmodulin-dependent protein kinase γ; CCT, chaperonin containing tailless complex polypeptide; CVB3, coxsackievirus B3; DBD, DNA-binding domain; DENV, dengue virus; EBNA1, Epstein–Barr nuclear antigen 1; ERK1, extracellular signal-regulated kinase 1; GSK3, glycogen synthase kinase 3; HBV, hepatitis B virus; HCMV, human cytomegalovirus; HIV, human immunodeficiency virus; Hop, heat-shock organizing protein; HR-AB, heptad repeat regions A and B; HSE, heat shock response elements; HSF1, Heat shock factor 1; HSFs, Heat shock factors; HSP70, heat shock protein of 70 kDa; HSP90, heat shock protein of 90 kDa; HSPs, Heat shock proteins; HSV-1, herpes simplex virus 1; HSV-2, herpes simplex virus 2; IRES, internal ribosome entry site; LRAs, latency-reversing agents; LTR, long terminal repeat; p38 MAP, p38 mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; TRiC, tailless complex polypeptide 1 ring complex; UPR, unfolded protein response; VACV, vaccinia virus.
unfolded protein response (UPR) has also been reported to be related to heat shock stress components, such as HSF1 and HSP47 [7,8].

Seven members of the HSF family have been identified in eukaryotes: HSF1-HSF5, HSFY, and HSFX [9,10]. At present, relatively little is known regarding the roles of HSF5, HSFY, and HSFX [11]. On the contrary, HSF1-HSF4 have been isolated in vertebrates and more extensively studied, as well as the single HSF gene known to date to be encoded in yeast [5,12]. Additionally, HSF1, HSF2, and HSF4 are expressed as different isoforms [5,12,13]. HSF2α and HSF2β are expressed in vertebrates, and HSF2 has been reported to act as a transcriptional regulator for the HSF1-dependent activation of HSP genes [14,15]. Additionally, it has been shown that HSF2 is not activated by heat shock, but nevertheless colocalizes and interacts with HSF1 [16,17]. Interestingly, neither HSF4 nor its two HSF4 isoforms, namely HSFXα and HSFXβ, are activated by heat shock [12,18]. In fact, it has been reported that these HSF4 isoforms have opposing effects on the basal levels of chaperone gene expression, with HSFXα attenuating the expression of these genes and consequently the induction of HSPs, likely due to a direct competition with HSF1 at binding to HSEs, while HSFXβ induces the transcription of heat shock response genes [12,19].

Four isoforms of HSF1 have been reported to date: HSF1α, HSF1β, HSF1γ, and HSF1γβ [10,20]. HSF1 is formed by an N-terminal winged helix-turn-helix DNA-binding domain and hydrophobic heptad repeat regions A and B (HR-A/B), which are thought to act as a leucine zipper coiled-coil trimerization domain [21–25]. There is also a regulatory domain, HR-C and a C-terminal transcription activation domain [21,23–25]. Under non-stress conditions, HSF1 is in a monomeric form and is associated as a complex with molecular chaperones, such as the HSP of 70 kDa (HSP70), or the HSP of 90 kDa (HSP90), and it is also regulated by the tailless complex polypeptide 1 ring complex (TRiC), also known as the chaperonin containing tailless complex polypeptide 1 (CCT) [26–30].

Heat shock factor 1 strongly participates in response to heat shock by inducing the expression of HSR genes, such as molecular chaperones or HSPs [1,6,31]. These proteins play major roles in the HSR by promoting cell survival [1,6]. However, the role of HSF1 is much wider, involving functions beyond the HSR [6]. Over the last decades, this transcription factor has been reported to participate in multiple cellular processes, such as apoptosis, the unfolded protein response (UPR) in the endoplasmic reticulum, oxidative stress, autophagy, multidrug resistance, and physiological development, among others [3,6,8].

Additionally, a role between HSF1 and viral infections has been described, although in a somewhat limited manner despite the fact that HSPs are known to participate in many processes related to viral infection, such as viral entry, viral replication, and viral gene expression, among others [32]. Furthermore, it is unknown if HSF1 may have a potential as a new therapeutic target for different viral infections. Given that new drugs that block or activate HSF1 are currently being tested in clinical trials, we sought studies that relate HSF1 with viral infection and found that because this transcription factor participates in the replication cycle of many viruses, its modulation could eventually exert a favorable influence over the host’s ability to control or resolve viral infections [33–35].

Here, we review aspects related to HSF1 activation and discuss what is known regarding the role of HSF1 during viral infections.

**HSF1 activation**

Heat stress, which may be considered as temperatures between 39 and 43 °C, the presence of heavy metals, oxidants, or proteotoxins induce the homotypic-merization of HSF1, its dissociation from chaperones, and its phosphorylation which leads to its active form [28,36–38]. Because fever frequently occurs upon viral infections, HSF1 activation may be common during viral infections, although this has not been studied extensively [36,39].

In its homotrimer form, HSF1 transllocates to the nucleus, which leads to its accumulation in this compartment [40,41]. Here, it can bind to specific DNA sequences in the genome named heat shock elements (HSE), which are usually located in the upstream untranslated region of target genes [1,6,42]. HSE are composed of a small pentameric consensus sequence containing the xGAAx motif [42]. However, a stable association between HSF1 and DNA requires three overlapped pentameric sequences with the following composition TTCxxGAAxxTTC [4]. Once HSF1 binds to the DNA, it will upregulate the transcription of the genes encoding this element, many of which are HSPs [1,3,32].

Interestingly, the activation of this transcription factor is mediated by both protein–protein interactions and post-translational modifications which are discussed below in the following paragraphs [21,38]. Furthermore, different studies suggest that the activation cycle of this transcription factor is highly regulated [21,24,25,38]. Indeed, it is thought that HSF1 is
activated by different mechanisms based on the type of stress, with its activation depending on whether the stimulus is thermal or non-thermal [3].

Multiple factors are believed to be involved in the activation of HSF1. For instance, it has been reported that temperature increases cause intrinsic structural changes in HSF1 that support its oligomerization and activation [43]. Temperature-induced conformational dynamics of HSF1 revealed that at 20 °C only few regions of this protein, such as the DNA-binding domain (DBD), the oligomerization domain (LZ1-3) and HR-C are structured [3,43]. Furthermore, it has been reported that at higher temperatures there is a temperature-dependent unfolding process of HR-C, which is known to repress HSF1 trimerization via a coiled-coil interaction with HR-A, or HR-B in non-stressed cells [24,43]. The unfolding of HR-C leads to the stabilization of HR-A/B, which is known as the trimerization domain [24,43]. This finding indicates that HSF1 has an intrinsic capacity to sense temperature changes. Interestingly, the temperature at which HSF1 is activated has been shown to be tissue-dependent [44]. Additionally, differential temperature sensitivities have been observed for this transcription factor in different organisms, even with identical primary protein sequences [44]. This finding suggests that it is likely that cell-specific protein–protein interactions with HSF1 can also modulate the structure of this protein and alter the thresholds required for its stabilization involved in its activation.

Importantly, there is a negative autoregulatory feedback loop, which guarantees that HSF1 HSRs occur at a level consistent with the extent of the protein damage in the cell [30,45]. For instance, some HSPs induced by HSF1, such as HSP70, HSP72, and HSP90, can inhibit HSF1 by impairing the formation of new active HSF1 trimers, by directly binding to the HSF1 trimerization domain [6,30]. The unfolding of HR-C leads to the stabilization of HR-A/B, which is known as the trimerization domain [24,43]. This finding indicates that HSF1 has an intrinsic capacity to sense temperature changes. Interestingly, the temperature at which HSF1 is activated has been shown to be tissue-dependent [44]. Additionally, differential temperature sensitivities have been observed for this transcription factor in different organisms, even with identical primary protein sequences [44]. This finding suggests that it is likely that cell-specific protein–protein interactions with HSF1 can also modulate the structure of this protein and alter the thresholds required for its stabilization involved in its activation.

HSF1 and viral infections

Although HSPs play important roles in the replication cycle of many viruses, as extensively reviewed by Wan et al. [32], the role of HSF1 in viral infections has been scarcely described. This is particularly surprising, given that a sudden increase in body temperature, such as might occur with fever is a frequent host response during viral infections, and thus, HSF1 may be activated under these circumstances and have an impact on the progression of the infections [60,61]. Consequently, its modulation may impact the host–pathogen interaction [38,39,62].

At present, most studies evaluating a role for HSF1 in viral infections are focused on the activation of this transcription factor during infection caused by the human immunodeficiency virus (HIV). To date, HSF1 has been reported to participate in the transcription of HIV genes and the reactivation of this virus from latency [62]. HSF1 has been found to bind to the 5′-LTR of HIV, which leads to viral reactivation and the recruitment of multi-subunit complexes, such as p300 which is recruited by HSF1 for self-acetylation and p-TEBP that is involved in the regulation of transcription [62]. Importantly, knocking out the gene encoding for HSF1 in 293T cells (293T-HSF1-KO; 4/−10 bp)
led to impaired transcription of viral genes [62]. Conversely, the overexpression of HSF1 increased the transcription of HIV genes [62]. Thus, HSF1 positively regulates the transcription of latent HIV. Additionally, HSF1 has been described to be constitutively active in T cells latently infected with HIV and to likely contribute to viral reactivation. Therefore, HSF1-mediated HIV reactivation may occur in response to stress factors over these cells, such as starvation or increased temperature due to fever [62].

Furthermore, in vitro studies have shown that the mechanism of action of some latency-reversing agents (LRAs) involves a HSF1-mediated stress pathway [63]. Consequently, the inhibition of HSF1 decreased latency reversal, and thus negatively modulating this factor holds the potential to delay the acquired immunodeficiency syndrome (AIDS) [63]. Additionally, HSF1 stimulates HIV elongation via the recruitment of p-TEFb to the viral long terminal repeat (LTR), and the inhibition of HSF1 dampens the formation of elongated HIV-1 transcripts [63]. Moreover, Nef (an HIV protein)-dependent induction of HSP40 has been reported to lead to increased HIV gene expression [64], and HSF1 binds directly to a HSF1-binding sequence in the HIV LTR promoter, which leads to an increase in viral gene expression and replication [64].

Fig. 1. HSF1 activation. HSF1 is usually present in the cell in an inactivated form. Inactivation of HSF1 occurs mainly by three mechanisms: (1a) HSP90 binding to HSF1, (1b) HSF1 stabilization through the formation of a leucine zipper structure within the protein (red lines), or (1c) through post-transcriptional modifications, such as acetylation, sumoylation, and phosphorylation. (2) HSF1 is activated when an increase in misfolded proteins occurs in the cell, such as after heat shock (increased environmental temperature). HSF1 activation involves the release of monomeric HSF1 from chaperones, such as HSP20 and HSP90 (3a). Once activated, HSF1 monomers interact together to form a trimer that is stabilized by leucine zippers (red lines) (3b) and is phosphorylated by the calcium/calmodulin-dependent protein kinase II gamma (CaMKII gamma). (4) HSPs act as molecular chaperones for the correct folding of numerous proteins in the cell. (5) HSF1 binds to DNA sequences in the genome, namely heat shock elements (HSE) in the promoters of genes encoding for heat shock responses, such as heat shock proteins (HSPs) promoting their transcription. HSF1 also promotes the transcription of genes involved in the regulation of apoptosis, DNA repair, modulation of drug resistance, unfolded protein response (UPR) at the endoplasmic reticulum, autophagy, and oxidative stress, among others. (6) Acetylation (blue circles) of HSF1 at Lys80 destabilizes its interaction with the DNA. HSP40 together with HSP70 bind to specific sites in HSF1 monomers leading to a destabilization of the trimer. (7) Excess HSF1 is degraded through the SCFbeta-TrCP pathway, and only a basal amount of inactive HSF1 remains in the cell.
findings suggest that HSF1-mediated signaling plays a role in HIV-1 transcriptional elongation.

However, stress-independent activation of HSF1 can reduce the quantity and infectivity of HIV virions in a lymphoblastic cell line [65]. Surprisingly, this inhibition continued throughout three consecutive passages, without recovering viral titers [65]. Thus, the role of HSF1 in HIV infection is yet to be fully elucidated, as altogether there seem to exist some paradoxical effects for HSF1 during infection with this virus.

On the contrary, HSF1 may act as an innate repressor of inflammation induced by HIV [66]. Indeed, HSF1 overexpression inhibits HIV-induced inflammatory responses in THP-1 cells (a human monocytic cell line), and contrarily, HSF1 deficiency is associated with an increased inflammatory response [66]. This effect was due to a competition between HSF1 and nuclear factor-kB (NF-kB) in the nucleus, with HSF1 having an inhibitory effect over NF-kB binding to the HIV long terminal repeats (LTRs), which leads to impaired transcription of viral genes and a reduced inflammatory response [66]. Thus, the inhibitory effect that HSF1 has over inflammatory responses could be further explored so that it could be used as a potential treatment for viral infections that induce inflammatory processes, such as SARS-CoV-2, the human papilloma virus, hepatitis C virus, and hepatitis B virus, among others.

A relation between HSF1 and the hepatitis B virus (HBV) has also been reported [67]. The p53-binding protein 2 (apoptosis-stimulating protein of p53-2, ASPP2) can inhibit HBV-induced hepatocyte autophagy in a p53-independent manner [67]. Furthermore, the inhibition of autophagy in hepatocytes has been reported to inhibit HBV replication. Interestingly, ASPP2 binds to HSF1 in HBV-infected cells, which in turn impedes its nuclear translocation. Importantly, the interaction between ASPP2 and HSF1 inhibits HSF1 nuclear translocation and inhibits the transactivation of the autophagy-related protein 7 (Atg7), with an overall reduction in hepatocyte autophagy [67]. These findings indicate that, by regulating Atg7 transcription, HSF1 enables ASPP2 to reduce autophagy in hepatocytes and, therefore, inhibit HBV replication.

During vaccinia virus (VACV) infection, the host mRNA transcriptome is reshaped with several genes being downregulated [68]. According to this study, 611 host genes were upregulated upon VACV infection and this subset of genes was strongly enriched in genes that are regulated by HSF1 [68]. Additionally, HSF1 was also upregulated after VACV infection and was reported to be phosphorylated, translocate to the nucleus, and to increase the transcription of HSF1-target genes [68]. Furthermore, the activation of this transcription factor supported viral replication and the inhibition of HSF1, as well as some targets of HSF1 such as HSP27, HSP70, and HSP90 blocked viral infection and replication [68], suggesting that HSF1, as well as HSF1-induced proteins and their pharmacological regulation, could be potential treatments against VACV.

On the contrary, a cell line which overexpresses constitutively activated HSF1 (cHSF1) was found to induce an oncolytic effect in in vitro and in vivo studies, by promoting the replication of oncolytic adenovirus Adel55 [69]. Additionally, the overexpression of cHSF1 through its insertion into Adel55 (Adel55-cHSF1) was found to induce a tumor-specific immune response when used as a strategy for cancer gene therapy in immunocompetent hosts [69]. Consequently, Adel55-cHSF1 induced a tumor-specific immune response in mice with tumors [69].

Furthermore, a role for HSF1 in dengue virus (DENV) replication, both in vitro and in vivo, has also been assessed. HSF1 is activated during DENV infection in a Ca2+ and protein kinase A-dependent manner [70]. Interestingly, the inhibition of HSF1 reduced DENV replication in THP-1 cells and in primary human monocytes [70]. On the contrary, activated HSF1 induced DENV replication via the upregulation of Atg7, which is related to autophagy and is crucial for the replication of this virus [70]. The activation of HSF1 by heat stress also facilitated DENV replication, and in virus-infected brains, the presence of activated HSF1 increased Atg7 and the induction of autophagy [70]. Consistently, the inhibition of HSF1 in this context resulted in reduced autophagy, as well as a reduction in viral protein expression, neuropathy, and mortality [70]. Therefore, the activation of HSF1 may be beneficial during DENV infections, and therefore, its inhibition may be a potential therapeutic strategy.

Additionally, increased temperature conditions have been reported to induce the transcription of the Epstein–Barr nuclear antigen 1 (EBNA1) in EBV-transformed B95-8 and LCL cell lines (a marmoset B cell line transformed by EBV and a EBV-transformed human B cell line, respectively), which arose from the Q promoter (Qp)-initiated transcripts [71]. This viral protein is consistently expressed in all malignancies associated with EBV, and it is reported to be crucial for the initiation of viral DNA replication, with Qp being the key promoter that regulates its expression [71]. Importantly, a high affinity and functional HSE was found in the Qp, and furthermore, HaCaT cells (a spontaneously transformed human keratinocyte cell line) co-transfected with a plasmid encoding HSF1 and Qp-luciferase displayed increased Qp activity [71]. Consistently, HSF1 gene silencing with interference
RNA resulted in attenuated heat-induced EBNA1 expression, indicating that EBNA1 expression is regulated by HSF1 [71]. Thus, it is likely that HSF1 may regulate the expression of EBNA1 through its binding to an HSE in the Qp promoter.

The human cytomegalovirus (HCMV) is able to expand the lifespan of monocytes through the stimulation of a non-canonical Akt pathway after viral entry, which in turn leads to the increased expression of antiapoptotic proteins [72]. Interestingly, a relation between HCMV-activated Akt and HSF1 has been described [72]. Activation of Akt during HCMV infection activates HSF1, which in turn upregulates the mTOR pathway that promotes the synthesis of cap- and internal ribosome entry site (IRES)-containing mRNAs that encode antiapoptotic proteins [72]. Interestingly, the switch from cap-dependent to IRES-mediated translation usually occurs under conditions of cellular stress [72]. Thus, HCMV may benefit from HSF1 activation in order to induce the synthesis of certain proteins.

The coxsackievirus B3 (CVB3) is known to exploit host cellular machineries during its replication cycle and to interact with host chaperones, such as HSP70 [73]. A cap-independent translation of this protein has been described during viral infection, possibly due to an IRES within the mRNA of the HSP70 transcript [73]. Interestingly, upon CVB3 infection, the Ca\(^{2+}\)/calmodulin-dependent protein kinase \(\gamma\) (CaMKII\(\gamma\)) has been reported to be activated, which leads to the activation of HSF1 due to the phosphorylation of a serine residue in position 230 of this protein, and the consequent enhancement of \(HSP70\) transcription [73]. Additionally, it has been reported that HSP70-1 (a member of the HSP 70 protein family) stabilizes the CVB3 genome through its binding to an AU-rich element (ARE) present in the 3' untranslated region of the CVB3 RNA, which favors viral replication and enhances immune infiltration into the heart during the development of infection-mediated myocarditis [73]. Therefore, activation of HSF1 and the consequent upregulation of HSP70 is beneficial for CVB3 [73]. How CVB3 infection leads to CaMKII\(\gamma\)- and consequently HSF1 activation is yet unknown, but it is thought to be through a phosphorylation of a threonine residue (Thr286) in CaMKII\(\gamma\) [73]. The participation of HSF1 in the replication cycle of the viruses discussed above is summarized in Fig. 2.

**Interrelationship between HSF1 and HSPs**

The HSP family is composed of five subfamilies, which are classified according to their molecular weight, namely HSP60, HSP70, HSP90, HSP100, and a subfamily of small HSPs [74,75]. The main drivers of the transcription of HSPs are HSFs [28]. Once HSF1 is oligomerized into its active homotrimer, it binds to the HSE of target genes, which leads to a rapid increase in the transcription of genes encoding proteins such as HSP90 and other chaperones such as HSP27, HSP40, and HSP70 [32,76,77].

Heat shock proteins play an important role in regulating the activity of HSF1. Under non-stress conditions, HSF1 occurs in its monomeric form associated with molecular chaperones, mostly with HSP90 [27,78]. Thus, in normal conditions HSFs are sequestered by molecular chaperones and these proteins form a multi-molecular chaperone complex composed by HSPs, such as HSP40, HSP70, and HSP90, and other proteins such as 14-3-3 which contribute to the repression of this transcription factor [28–30]. When heat stress is present, HSP90 is released from HSF1, due to an increase in misfolded proteins that are sensed by the molecular chaperone, which allows HSF1 to form a homotrimer and its activation [29,79].

A reduced expression of HSP90, but not of other HSR proteins, such as HSP70, heat-shock organizing protein (Hop), and HSP40, induces the activation of HSF1, without inducing the transcription of HSP genes, and thus the inhibition of HSP90 is not the only factor needed to induce the transcription of HSPs [80,81]. Interestingly, HSP90 has been shown to inhibit HSF1 activation and the binding of the latter to target DNA, whereas HSP70 inhibits the transactivation capacity of HSF1 [82]. Additionally, other studies have also reported that HSP40 and HSP70 inhibit the transactivation capacity of HSF1, likely due to the recruitment of the HSP70-interacting transcriptional co-repressor CoREST [82,83]. However, the exact role that these chaperones play in HSF1 modulation is still controversial due to contradictory findings. For instance, the use of geldanamycin, an HSP90 inhibitor, results in HSF1 activation [80]. On the contrary, in vitro studies in which heat stress was applied, it was found that HSP90 induces HSF1 trimerization [27,43]. Additionally, in vivo experiments show that the overexpression of HSP70 alone is not sufficient to suppress HSF1 DNA-binding, but may play a role in the inactivation of this transcription factor after prolonged thermal stress [29,30]. Interestingly, in human cells treated with sodium salicylate, HSF1 oligomerized and bound to the promoter of target genes such as \(HSP70\), but its transcription was not induced [84]. Thus, oligomerization of HSF1 alone is not sufficient for promoting the transcriptional activity of this transcription factor.

Due to the diverse roles played by HSPs in viral infections (extensively reviewed by Wan et al. [32]), a...
close look into the factors promoting the expression of these proteins could provide further insights on the role of HSF1 in the replication cycle of viruses and the identification of this transcription factor as a potential target for antiviral treatments.

**Pharmacological modulation of HSF1**

Heat shock factor 1 is being increasingly related to different pathologies, such as cancer and neurodegenerative diseases, and thus, interest is mounting on identifying drugs that modulate this transcription factor [85]. For instance, high levels of HSF1 correlate with poor prognosis in cancer patients [86,87]. Additionally, HSF1 has been reported to drive oncogenesis by mediating the activation of genes that enable the initiation and maintenance of cancer cells through shifts in processes such as cell cycle control, metabolism, protein translation, and proliferation [88]. This has led to the assessment of different HSF1 inhibitors, such as the drug named NXP800, which is being tested in a phase I clinical trial. This drug has been shown to...
increase apoptosis of cancer cells in ovarian clear cell carcinoma (ClinicalTrials.gov Identifier: NCT05226507) [89]. Another HSF1 inhibitor is DTHIB, which has been extensively investigated and has been directly related to a reduction in the viability of prostate cancer cells, by decreasing the expression of antiapoptotic genes [90]. These drugs have not been tested in the context of viral infection, yet they may have effects that limit viral progression through the inhibition of HSF1.

Another drug that inhibits HSF1 with potential antiviral effects is KRIIBB11. This drug binds directly to HSF1 and inhibits its interaction with target sequences in the DNA. KRIIBB11 has been reported to significantly decrease the transcription of HSF1-controlled genes, such as HSP70, EGFR, MET, and AXL and to promote the death of lung, glioblastoma, and myeloma cancer cells [91–93]. CCT261236 is a drug that decreases the activity of HSF1 and consequently the expression of HSPs [93]. Again, the potential antiviral activities of these drugs have been poorly assessed or not assessed at all. Two other inhibitors of HSF1 activity, and consequently HSP expression, are triptolide and KNK437, which promote the death of immortalized cells [94,95]. For the latter, a pro-apoptotic effect was seen through the downmodulation of the antiapoptotic proteins BCL2 and MCL1 in L363 cells [95].

On the contrary, drugs that promote HSF1 activity are also being evaluated as potential treatments, namely in the context of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis [3]. One such drug is HSF1A, which positively modulates HSF1 as corroborated by an observed increase in HSP70 and HSP25 expression after treatment with this compound in a dose-dependent manner [96]. Noteworthy, HSF1A specifically interacts with the TRiC/CCT complex and induces the activation of HSF1, which suggests a possible regulatory role for the TRiC/CCT complex over HSF1 [96].

Alternatively, due to the association between HSP90 or HSP70 and HSF1, some drugs aimed at positively modulating the activity of HSF1 target these chaperones, in order to release HSF1 so that it can exert its activity. One of these drugs, named geranylgeranylacetone (GGA) which targets HSP70 [97–99], while geldanamycin (17-AAG) [100] and riluzole [101,102] target HSP90. Whether these HSF1-activating drugs may have antiviral effects remains unknown and thus should be determined experimentally to define if such an approach may have potential antiviral potential.

On the contrary, Celastrol activates HSF1 and leads to an increase in energy expenditure, increased insulin resistance, increased mitochondrial function in fat tissue and muscle cells, as well as hepatic steatosis in a high-fat diet in 10T1/2 cells and primary fat SVF cells [103]. Regulation of energy expenditure is accomplished by the activation of PGC1α, a transcriptional coactivator that is a central inducer of mitochondrial biogenesis in cells and which modulates metabolic programing in adipose tissues and muscle [103]. The mechanisms of action of the different drugs targeting HSF1 and the pathologies in which they have been described are summarized in Table 1.

### Concluding remarks

Heat shock factor 1 is not only directly activated in response to increased temperature, but many other triggers also activate HSF1, or can modulate its threshold of activation. Importantly, several studies show that this transcription factor plays significant roles in the replication cycle of some viruses and that its involvement is independent of heat shock. The latter suggests that either viral determinants or host factors modulated by viral infection are impacting directly on HSF1 or on factors that regulate its function. Given that virus-infected cells may undergo some level of UPR due to sustained viral protein translation during infection, it is also possible that a link may exist between this response and HSF1 [7,8,104]. Given that a negative feedback loop between HSPs and HSF1 allows the regulation of HSF1 function, it will be of interest to assess this potential relationship in depth in the context of viral infections that interact with HSPs or induce their expression and to determine what is the contribution of HSF1 activation during the replication cycle of different viruses.

Additionally, it will also be important to evaluate the effect of varying levels of HSF1 expression in different cell types on the modulation of this transcription factor over viral infections, as HSF1 is not equally expressed among cell types and its expression will differ depending on environmental and cellular conditions [44]. Also, it will be beneficial for future research to explore whether a relation between viral infections and other HSF members exists, given the similarities and differences between the transcription factors in this family.

Because multiple drugs that positively or negatively modulate HSF1 activity are currently being tested in clinical trials for cancer and neurodegenerative diseases, it will be interesting to evaluate whether these drugs have positive or negative effects
for the host in the context of viral infections, potentially serving as novel strategies to counteract viral replication in the infected individual. To our knowledge, to date there are no reports describing the use of such drugs to target HSF1 in the context of viral infections.

Although there is very little information regarding the effect that the modulation of HSF1 activity may have over viral infections, there are multiple connections between gene products associated with this transcription factor and viral infections. Thus, we foresee that targeting HSF1 will be an interesting new approach for the treatment of viral infections, given the constant need for identifying and developing new drugs to combat this type of pathogens. Yet, it is important to note that altogether it will be necessary to corroborate that modulating HSF1 in the host will not harm the individual, particularly in scenarios in which there are significant increases in body temperature, such as during fever, as in this case altering the function of HSF1 could be deleterious for the host’s tissues.

Acknowledgements

This work was funded by Agencia Nacional de Investigación y Desarrollo (ANID)—Millennium Science Initiative Program—ICN09_016/ICN 2021_045: Millennium Institute on Immunology and Immunotherapy (ICN09_016/ICN 2021_045; former P09/016-F) and FONDECYT grants #1190864 and #1190830 from the Agencia Nacional de Investigación y Desarrollo (ANID). This work was also supported by the Regional Government of Antofagasta through the Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0). MF is ANID fellows #21191390.

Conflict of interest

The authors declare no conflict of interest.
Data accessibility
The data that supports this review is available and was found in PubMed at https://pubmed.ncbi.nlm.nih.gov.

Author contributions
All authors wrote and reviewed the manuscript. AN, BD, and PG designed the figures.

REFERENCES
1 Åkerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol. 2010;11:545–55.
2 Trinklein ND, Murray JI, Hartman SJ, Botstein D, Myers RM. The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol Biol Cell. 2004;15:1254–61.
3 Gomez-Pastor R, Burchfiel ET, Thiele DJ. Regulation of heat shock transcription factors and their roles in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:4–19.
4 Jaeger AM, Makley LN, Gestwicki JE, Thiele DJ. Genomic heat shock element sequences drive cooperative human heat shock factor 1 DNA binding and selectivity. J Biol Chem. 2014;289:30459–69.
5 Pirkkala L, Nykänen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001;15:1118–31.
6 Barna J, Csermely P, Vellai T. Roles of heat shock factor 1 beyond the heat shock response. Cell Mol Life Sci. 2018;75:2897–916.
7 Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421–38.
8 Kim E, Sakata K, Liao F-F. Bidirectional interplay of HSF1 degradation and UPR activation promotes tau hyperphosphorylation. PLOS Genet. 2017;13:e1006849.
9 Fujimoto M, Nakai A. The heat shock factor family and adaptation to proteotoxic stress: evolution and function of the HSF family. FEBS J. 2010;277:4112–25.
10 Neuder A, Achilli F, Moussaoui S, Bates GP. Novel isoforms of heat shock transcription factor 1, HSF1γα and HSF1γβ, regulate chaperone protein gene transcription. J Biol Chem. 2014;289:19894–906.
11 Westerheide SD, Raynes R, Powell C, Xue B, Uversky VN. HSF transcription factor family, heat shock response, and protein intrinsic disorder. Curr Protein Pept Sci. 2012;13:86–103.
12 Tanabe M, Sasai N, Nagata K, Liu X-D, Liu PCC, Thiele DJ, et al. The mammalian HSF4Gene generates both an activator and a repressor of heat shock genes by alternative splicing. J Biol Chem. 1999;274:27845–56.
13 Fiorenza MT, Farkas T, Dissing M, Kolding D, Zimarino V. Complex expression of murine heat shock transcription factors. Nucleic Acids Res. 1995;23:467–74.
14 He H, Soncin F, Grammatikakis N, Li Y, Siganou A, Gong J, et al. Elevated expression of Heat Shock Factor (HSF) 2A stimulates HSF1-induced transcription during stress. J Biol Chem. 2003;278:35465–75.
15 Goodson ML, Park-Sarge OK, Sarge KD. Tissue-dependent expression of heat shock factor 2 isoforms with distinct transcriptional activities. Mol Cell Biol. 1995;15:5288–93.
16 Sistonen L, Sarge KD, Phillips B, Abravaya K, Morimoto RI. Activation of heat shock factor 2 during hemin-induced differentiation of human erythroleukemia cells. Mol Cell Biol. 1992;12:4104–11.
17 Alastalo T-P, Hellesuo M, Sandqvist A, Hietakangas V, Kallio M, Sistonen L. Formation of nuclear stress granules involves HSF2 and coincides with the nucleolar localization of Hsp70. J Cell Sci. 2003;116:3557–70.
18 Nakai A, Tanabe M, Kawazoe Y, Inazawa J, Morimoto RI, Nagata K. HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. Mol Cell Biol. 1997;17:469–81.
19 Zhang Y, Freitag W, Dai R, Mivechi NF. Heat shock factor-4 (HSF-4a) is a repressor of HSF-1 mediated transcription. J Cell Biochem. 2001;82:692–703.
20 Goodson ML, Sarge KD. Regulated expression of heat shock factor 1 isoforms with distinct leucine zipper arrays via tissue-dependent alternative splicing. Biochem Biophys Res Commun. 1995;211:943–9.
21 Wu C. Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol. 1995;11:441–69.
22 Damberger FF, Pelton JG, Harrison CJ, Nelson HCM, Wemmer DE. Solution structure of the DNA-binding domain of the heat shock transcription factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Protein Sci. 1994;3:1806–21.
23 Neef DW, Jaeger AM, Thiele DJ. Genetic selection for constitutively trimerized human HSF1 mutants identifies a role for coiled-coil motifs in DNA binding. G3: Genes - Genomes - Genetics. 2013;3:1315–24.
24 Neudegger T, Verghese J, Hayer-Hartl M, Hartl FU, Bracher A. Structure of human heat-shock transcription factor 1 in complex with DNA. Nat Struct Mol Biol. 2016;23:140–6.
25 Rabindran SK, Haroun RI, Clos J, Wisniewski J, Wu C. Regulation of heat shock factor trimer formation:
26 Ali A, Bharadwaj S, O’Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. *Mol Cell Biol.* 1998;18:4949–60.

27 Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 Complex) that forms a stress-sensitive complex with HSF1. *Cell.* 1998;94:471–80.

28 Anckar J, Sistonen L. Regulation of HSF1 function in the heat stress response: implications in aging and disease. *Annu Rev Biochem.* 2011;80:1089–115.

29 Neef DW, Jaeger AM, Gomez-Pastor R, Willmund F, Frydman J, Thiele DJ. A direct regulatory interaction between chaperonin TRIC and stress-responsive transcription factor HSF1. *Cell Rep.* 2014;9:955–66.

30 Shi Y, Mosser DD, Morimoto RI. Molecular chaperones as HSF1-specific transcriptional repressors. *Genes Dev.* 1998;12:654–66.

31 Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. *Annu Rev Biochem.* 2009;78:959–91.

32 Wan Q, Song D, Li H, He M. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development. *Signal Transduct Target Ther.* 2020;5:125.

33 Dong B, Jaeger AM, Hughes PF, Loiselle DR, Hauck J, Fu Y, et al. Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. *Sci Transl Med.* 2020;12:eaabb5647. https://doi.org/10.1126/scitranslmed.abb5647

34 Sharma C, Seo Y. Small molecule inhibitors of HSF1-activated pathways as potential next-generation anticancer therapeutics. *Molecules.* 2018;23:2757.

35 Fujikake N, Takeuchi T, Nagai Y. HSF1 activation by small chemical compounds for the treatment of neurodegenerative diseases. In: Nakai A, editor. *Heat shock factor.* Tokyo: Springer Japan; 2016. p. 277–92.

36 Hasday JD, Singh IS. Fever and the heat shock response: distinct, partially overlapping processes. *Cell Stress Chaperones.* 2000;5:471.

37 Larson JS, Schuetz TJ, Kangue RE. In vitro activation of purified human heat shock factor by heat. *Biochemistry.* 1995;34:1902–11.

38 Xu Y-M, Huang D-Y, Chiu J-F, Lau ATY. Post-translational modification of human heat shock factors and their functions: a recent update by proteomic approach. *J Proteome Res.* 2012;11:2625–34.

39 Singh IS, Hasday JD. Fever, hyperthermia and the heat shock response. *Int J Hyperthermia.* 2013;29:423–35.

40 Mercier PA, Winegarden NA, Westwood JT. Human heat shock factor 1 is predominantly a nuclear protein before and after heat stress. *J Cell Sci.* 1999;112(Pt 16):2765–74.

41 Sarge KD, Murphy SP, Morimoto RI. Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. *Mol Cell Biol.* 1993;13:1392–407.

42 Amin J, Ananthan J, Voellmy R. Key features of heat shock regulatory elements. *Mol Cell Biol.* 1988;8:3761–9.

43 Hentze N, Le Breton L, Wiesner J, Kempf G, Mayer MP. Molecular mechanism of thermosensory function of human heat shock transcription factor Hsf1. *eLife.* 2016;5:e11576.

44 Gothrath LQ, Ruffner ME, Woodward JG, Park-Sarge O-K, Sarge KD. Lowered temperature set point for activation of the cellular stress response in T-lymphocytes. *J Biol Chem.* 2003;278:9322–6.

45 Voellmy R. On mechanisms that control heat shock transcription factor activity in metazoan cells. *Cell Stress Chaperones.* 2004;9:122.

46 Chu B, Zhong R, Soncin F, Stevenson MA, Calderwood SK. Transcriptional activity of heat shock factor 1 at 37 oC is repressed through phosphorylation on two distinct serine residues by glycogen synthase kinase 3α and protein kinases Cε and Cζ. *J Biol Chem.* 1998;273:18640–6.

47 Wang X, Grammatikakis N, Siganou A, Stevenson MA, Calderwood SK. Interactions between extracellular signal-regulated protein kinase 1, 14-3-3ε and protein kinase Cζ before and after heat stress. *J Biol Chem.* 2004;279:49460–9.

48 Calderwood SK, Wang Y, Xie X, Khailemaque M, Chou SD, Murshed A, et al. Signal transduction pathways leading to heat shock transcription. *Signal Transduct Insights.* 2010;2:ST1_S399.

49 Altman AM, Mahmud J, Nikolosvka-Coleska Z, Chan G. HCMV modulation of cellular PI3K/AKT/mTOR signaling: new opportunities for therapeutic intervention? *Antiviral Res.* 2019;163:82–90.

50 Cheshenko N, Trepanier JB, Stefanidou M, Buckley N, Gonzalez P, Jacobs W, et al. HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. *FASEB J.* 2013;27:2584–99.

51 Gong J, Shen X, Chen C, Qiu H, Yang R. Down-regulation of HIV-1 infection by inhibition of the MAPK signaling pathway. *Virol Sin.* 2011;26:114–22.

52 Akbay B, Shmakova A, Vassetzky Y, Dokudovskaya S. Modulation of mTORC1 signaling pathway by HIV-1. *Cells.* 2020;9:1090.

53 Dhamanase AS, Thakar MR, Paranjape RS. HIV-1-mediated suppression of IFN-α production is associated with inhibition of IRF-7 translocation and...
PI3K/akt pathway in plasmacytoid dendritic cells. *AIDS Res Hum Retroviruses.* 2019;35:40–8.

54 Tu W, Gong J, Tian D, Wang Z. Hepatitis B virus X protein induces SATB1 expression through activation of ERK and p38MAPK pathways to suppress anoikis. *Dig Dis Sci.* 2019;64:3203–14.

55 Raychaudhuri S, Loew C, Körner R, Pinkert S, Theis M, Hayer-Hartl M, et al. Interplay of acetyltransferase EP300 and the proteasome system in regulating heat shock transcription factor 1. *Cell.* 2014;156:975–85.

56 Westerheide SD, Ancark J, Stevens SM, Sistonen L, Morimoto RI. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. *Science.* 2009;323:1063–6.

57 Hendriks IA, Lyon D, Young C, Jensen LJ, Vertegaal ACO, Nielsen ML. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. *Nat Struct Mol Biol.* 2017;24:325–36.

58 Zelin E, Freeman BC. Lysine deacetylases regulate the heat shock response including the age-associated impairment of HSF1. *J Mol Biol.* 2015;427:1644–54.

59 Jaeger AM, Pemble CW, Sistonen L, Thiele DJ. Structures of HSF2 reveal mechanisms for differential regulation of human heat-shock factors. *Nat Struct Mol Biol.* 2016;23:147–54.

60 Tsalik EL, Fiorino C, Aqiel A, Liu Y, Henaor R, Ko ER, et al. The host response to viral infections reveals common and virus-specific signatures in the peripheral blood. *Front Immunol.* 2021;12:741837.

61 Muzumdar S, Rothe MJ, Grant-Kels JM. The rash with maculopapules and fever in adults. *Clin Dermatol.* 2019;37:109–18.

62 Pan X-Y, Zhao W, Zeng X-Y, Lin J, Li M-M, Shen X-T, et al. Heat shock factor 1 mediates latent HIV reactivation. *Sci Rep.* 2006;6:26294.

63 Timmons A, Fray E, Kumar M, Wu F, Dai W, Bullen CK, et al. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. *Proc Natl Acad Sci USA.* 2020;117:15763–71.

64 Rawat P, Mitra D. Cellular heat shock factor 1 positively regulates human immunodeficiency virus-1 gene expression and replication by two distinct pathways. *Nucleic Acids Res.* 2011;39:5879–92.

65 Nekongo EE, Ponomarenko AL, Dewal MB, Butty VL, Browne EP, Shoulders MD. HSF1 activation can restrict HIV replication. *ACS Infect Dis.* 2020;6:1659–66.

66 Pan X, Lin J, Zeng X, Li W, Wu W, Lu WZ, et al. Heat shock factor 1 suppresses the HIV-induced inflammatory response by inhibiting nuclear factor-κB. *Cell Immunol.* 2018;327:26–35.

67 Wang S, Sun Y, Wang Y, Wang A, Kou B, Che Y, et al. ASPP2 inhibits hepatitis B virus replication by preventing nucleus translocation of HSF1 and attenuating the transactivation of ATG7. *J Cell Mol Med.* 2021;25:6899–908.

68 Filone CM, Caballero IS, Dower K, Mendillo ML, Cowley GS, Santagata S, et al. The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection. *PLoS Pathog.* 2014;10:e1003904.

69 Wang C, Dai Z, Fan R, Deng Y, Ly G, Lu G. HSF1 overexpression enhances oncolytic effect of replicative adenovirus. *J Transl Med.* 2010;8:44.

70 Tsai T-T, Chen C-L, Tsai C-C, Lin C-F. Targeting heat shock factor 1 as an antiviral strategy against dengue virus replication in vitro and in vivo. *Antiviral Res.* 2017;145:44–53.

71 Wang F-W, Wu X-R, Liu W-J, Liao Y-J, Lin S, Zong Y-S, et al. Heat shock factor 1 upregulates transcription of Epstein-Barr Virus nuclear antigen 1 by binding to a heat shock element within the BamHI-Q promoter. *Virolology.* 2011;421:184–91.

72 Peppenelli MA, Miller MJ, Altman AM, Cojohari O, Chan GC. Aberrant regulation of the Akt signaling network by human cytomegalovirus allows for targeting of infected monocytes. *Antiviral Res.* 2018;158:13–24.

73 Qiu Y, Ye X, Hanson PJ, Zhang HM, Zong J, Cho B, et al. Hsp70-1: upregulation via selective phosphorylation of heat shock factor 1 during coxsackieviral infection and promotion of viral replication via the AU-rich element. *Cell Mol Life Sci.* 2016;73:1067–84.

74 Kim LS, Kim JH. Heat shock protein as molecular targets for breast cancer therapeutics. *J Breast Cancer.* 2011;14:167.

75 Pigliucci M. Epigenetics is back! HSP90 and phenotypic variation. *Cell Cycle.* 2003;2:34–5.

76 Sakurai H, Enoki Y. Novel aspects of heat shock factors: DNA recognition, chromatin modulation and gene expression: HSF-HSE interaction. *FEBS J.* 2010;277:4140–9.

77 Mazaara GI, Daneri-Beccera C, Zgajnar NR, Lotufo CM, Galigniana MD. Gene expression regulation by heat-shock proteins: the cardinal roles of HSF1 and Hsp90. *Biochem Soc Trans.* 2018;46:51–65.

78 Gallo LI, Ghini AA, Piwien Pilipuk G, Galigniana MD. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity. *Biochemistry.* 2007;46:14044–57.

79 Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. *Nature.* 2003;426:895–9.

80 Labbadia J, Cunliffe H, Weiss A, Katsuya E, Sathasivam K, Seredenina T, et al. Altered chromatin
Role of heat shock factor 1 in viral infections

A. Reyes et al.

architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest. 2011;121:3306–19.

81 Fukada M, Hanai A, Nakayama A, Suzuki T, Miyata N, Rodriguez RM, et al. Loss of deacetylty activity of Hda6 affects emotional behavior in mice. PLoS One. 2012;7:e30924.

82 Tariq M, Nussbaumer U, Chen Y, Beisel C, Paro R. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc Natl Acad Sci USA. 2009;106:1157–62.

83 Gómez AV, Galleguillos D, Maass JC, Battaglioli E, Kukuljan M, Andrés ME. CoREST represses the heat shock response mediated by HSF1. Mol Cell. 2008;31:222–31.

84 Jurivich DA, Pachetti C, Qiu L, Welk JF. Salicylate triggers heat shock factor differently than heat. J Biol Chem. 1995;270:24489–95.

85 Carpenter RL, Göken-Polar Y. HSF1 as a cancer biomarker and therapeutic target. Curr Cancer Drug Targets. 2019;19:515–24.

86 Dai C, Sampson SB. HSF1: guardian of proteostasis in cancer. Trends Cell Biol. 2016;26:17–28.

87 Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci USA. 2011;108:18378–83.

88 Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol. 2013;87:19–48.

89 NXP800. Nuvectis Pharma. [cited 2022 Feb 25]. Available from: https://nuvectis.com/staging/5114/nxp800/

90 Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. [cited 2022 Jan 5]. Available from: https://www.science.org/doi/10.1126/scitranslmed.abb5647?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed

91 Lee S, Jung J, Lee Y-J, Kim S-K, Kim J-A, Kim B-K, et al. Targeting HSF1 as a therapeutic strategy for multiple mechanisms of EGFR inhibitor resistance in EGFR mutant non-small-cell lung cancer. Cancers. 2021;13:2987.

92 Yoo K, Yun H-H, Jung S-Y, Lee J-H. KR1BB1 induces apoptosis in A172 glioblastoma cells via MULE-dependent degradation of MCL-1. Molecules. 2021;26:4165.

93 Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, et al. HSF1 is essential for myeloma cell survival and a promising therapeutic target. Clin Cancer Res. 2018;24:2395-407.

94 Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, et al. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol. 2013;160:465–76.

95 Bustany S, Cau J, Descamps G, Pellat-Deceunynck C, Sola B. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. J Hematol Oncol. 2015;8:40.

96 Neef DW, Turski ML, Thiele DJ. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010;8:e1000291.

97 Fujibayashi T, Hashimoto N, Jijiwa M, Hasegawa Y, Kojima T, Ishiguro N. Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model. BMC Pulm Med. 2009;9:45.

98 Zeng S, Wang H, Chen Z, Cao Q, Hu L, Wu Y. Effects of geranylgeranylacetone upon cardiovascular diseases. Cardiovasc Ther. 2018;36:e12331.

99 Lubbers NL, Polakowski JS, Wegner CD, Burke SE, Diaz GJ, Daniell KM, et al. Oral bimoclomol elevates heat shock protein 70 and reduces myocardial infarct size in rats. Eur J Pharmacol. 2002;435:79–83.

100 Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, et al. A phase I trial of twice-weekly 17-allylamino-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2006;12(20 Pt 1):6087–93.

101 Liu AYC, Mathur R, Mei N, Langhammer CG, Babiarz B, Firestein BL. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem. 2011;286:2785–94.

102 Yang J, Bridges K, Chen KY, Liu AY-C. Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection. PLoS One. 2008;3:e2864.

103 Ma X, Xu L, Alberobello AT, Gavrilova O, Bagattin A, Skarulis M, et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab. 2015;22:695–708.

104 Tognarelli EI, Retamal-Díaz A, Farias MA, Duarte LF, Palomino TF, Ibañez FJ, et al. Pharmacological inhibition of IRE-1 alpha activity in herpes simplex virus type 1 and type 2-infected dendritic cells enhances T cell activation. Front Immunol. 2022;12:764861.